De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus

Pediatric Nephrology

Volumn 30, Issue 4, 2015, Pages 693-697

  Cortina, Gerard ^a   Trojer, Raphaela ^a   Waldegger, Siegfried ^a   Schneeberger, Stefan ^a   Gut, Nadezda ^b   Hofer, Johannes ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Antibody mediated rejection; Atypical HUS; CFH polymorphisms; CNI induced TMA; De novo TMA

Indexed keywords

COMPLEMENT FACTOR H; CREATININE; EVEROLIMUS; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ANTIBODY MEDIATED REJECTION; ARTICLE; CASE REPORT; CHILD; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MINIMUM PLASMA CONCENTRATION; PERITONEAL DIALYSIS; PLASMAPHERESIS; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; CHEMICALLY INDUCED; THROMBOTIC MICROANGIOPATHIES;

CALCINEURIN INHIBITORS; CHILD; DRUG SUBSTITUTION; EVEROLIMUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; TACROLIMUS; THROMBOTIC MICROANGIOPATHIES;

EID: 84923673542     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-014-3036-8     Document Type: Article

References (15)

1. Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Frémeaux-Bacchi V (2013) Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13(3):663–675
2. Satoskar AA, Pelletier R, Adams P, Nadasdy GM, Brodsky S, Pesavento T, Henry M, Nadasdy T (2010) De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant 10(8):1804–1811
3. Caires RA, Marques ID, Repizo LP, Sato VA, Carmo LP, Machado DJ, de Paula FJ, Nahas WC, David-Neto E (2012) De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival. Transplant Proc 44(8):2388–2390
4. Liptak P, Ivanyi B (2006) Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol 2(7):398–404
5. Meehan SM, Kremer J, Ali FN, Curley J, Marino S, Chang A, Kadambi PV (2011) Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies. Clin J Am Soc Nephrol 6(2):395–403
6. Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, Licht C (2014) Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 40(4):444–464
7. Neumann HP, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, Cybulla M, Riegler P, Königsrainer A, Neyer U, Bock A, Widmer U, Male DA, Franke G, Zipfel PF (2003) Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 40:676–681
8. Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF, Silvestri G, Skerka C, Józsi M, Zipfel PF, Hageman GS, Smith RJ (2006) Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 43:582–589
9. Reynolds JC, Agodoa LY, Yan CM, Abbott KC (2003) Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 42:1858
10. Noris M, Remuzzi G (2010) Thrombotic microangiopathy after kidney transplantation. Am J Transplant 10:1517–1523
11. Devadoss CW, Vijaya VM, Mahesh E, Venkataramana SR, Girish MS (2012) Tacrolimus associated localized thrombotic microangiopathy developing in early stage after renal transplantation. J Clin Diagn Res 6:1786–1788
12. Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS (2003) De novo thrombotic microangiopathy in renal transplant recipients: a comparison of HUS with localized renal TMA. Am J Kidney Dis 41:471–479
13. Noone D, Al-Matrafi J, Tinckam K, Zipfel PF, Herzenberg AM, Thorner PS, Pluthero FG, Kahr WH, Filler G, Hebert D, Harvey E, Licht C (2012) Antibody mediated rejection associated with complement factor H-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 12(9):2546–2553
14. Hofer J, Rosales A, Fischer C, Giner T (2014) Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr 97:2296–2360
15. Keller K, Daniel C, Schöcklmann H, Endlich KH, Kerjaschki D, Johnson RJ, Hugo C (2006) Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol Dial Transplant 21:2724–2735